Organization Profile
Amgen
Organization Overview
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Today, we continue to push the boundaries by expanding our Data Science capabilities. Our Data Science team applies a variety of Data Science, Artificial Intelligence, and Machine Learning techniques from discovery to delivery, across the organization. Come by rewarded for the work you do and help make a meaningful difference for patients with serious illnesses. Every single day!
To learn more about Amgen’s Data Science Team, we invite you to read a recent WIRED Magazine interview with one of senior Data Scientists: http://bit.ly/Amgen_Data_Science
Discover what Amgen can do for you by visiting Careers.Amgen.com
Organization History
1980 - William Bowes from Cetus Corporation recruits Winston Salser from UCLA to start Amgen with a scientific advisory board consisting of Normam Davidson, Leroy Hood, Arnold Berk, John Carbon, Robert Schimke, Arno Motulsky, Marvin H. Caruthers, and Dave Gibson.
1989 - Amgen received approval for the first recombinant human erythropoetin product, Epogen, for the treatment of anemia associated with chronic kidney failure. Epogen (also marketed by Johnson and Johnson under the tradename Procrit) would later be approved for anemia due to cancer chemotherapy, anemia due to treatment with certain HIV drugs, and for the reduction of the need for transfusions associated with surgery.
1991 - In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy. A 2002 meta-analysis found that Neupogen treatment reduced the risk of febrile neutropenia by 38%, reduced the risk of documented infection by 49%, and reduced the risk of infection-related mortality by 40%.
1998 - In November 1998, Immunex, a future acquisition of Amgen, received approval for Enbrel (etanercept), the first rheumatoid arthritis drug targeting tumor necrosis factor alpha (TNF-alpha).[14] A 2006 assessment by the National Institute of Clinical Excellence of the United Kingdom concluded that etanercept and related rheumatoid arthritis drugs later introduced by competitors "are effective treatments compared with placebo for RA patients who are not well controlled by conventional DMARDs, improving control of symptoms, improving physical function, and slowing radiographic changes in joints. A more recent study demonstrated that compared to traditional disease-modifying anti-rheumatic drugs, treatment with etanercept improved survival, reduced cardiovascular events and reduced the incidence of hematological cancers.
2010 - On June 6, 2010 Amgen received FDA approval for Prolia, a protein drug for the treatment of post-menopausal osteoporosis. In clinical trials, Prolia reduced the rate of vertebral fractures by 61% and the risk of hip fractures by 40%.
2010 - In November 2010, the FDA approved Xgeva for the prevention of complications of bone metastases in patients with solid tumors. The clinical trials primarily enrolled patients with breast or prostate cancer.
2015 - In September 2015, the company announced it would acquire Dezima Pharma for more than $1.55 billion. The same day, the company announced a collaboration with Xencor on 6 early stage immuno-oncology and inflammation programs. As part of the deal, Amgen agreed to pay $45 million upfront, with the deal being worth up to another $1.7 billion.
2016 - In September 2016, the company announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment of multiple myeloma.
2017 - Cash returned to shareholders totaled a record $6.5 billion through dividends and share repurchases.
2018 - Amgen launched the first-in-class preventative drug treatment for adult migraines, Aimovig.
Notable Products / Brands
Revenue: US $22.99 billion (2016)
Notable Accomplishments / Recognition
Aimovig (erenumab-aooe) - For the preventive treatment of migraine in adults
Blincyto (blinatumomab) - For the treatment of Philadelphia chromosome-negative relapsed /refractory B cell precursor acute lymphoblastic leukemia
Corlanor (ivabradine) - For the treatment of chronic heart failure
Imlygic (talimogene laherparepvec) - For the treatment of unresectable recurrent melanoma
INFERGEN (interferon alfacon-1) - Treatment for chronic hepatitis C virus
Kineret - Injectable therapy for the treatment of rheumatoid arthritis
Neulasta - Treatment to decrease the chance of infection by febrile neutropenia in patients receiving chemotherapy
Neupogen - Treatment for slow white blood cell recovery following chemotherapy
Nplate (romiplostim) - For the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura
Parsabiv (etelcalcetide) - For the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis
Prolia (denosumab) - For the treatment of postmenopausal women with osteoporosis at high risk for fracture
Repatha (evolocumab) - For the treatment of high cholesterol
Sensipar (cinacalcet) - For the treatment of secondary hyperparathyroidism and hypercalcemia in parathyroid carcinoma patients
Vectibix (panitumumab) - For the treatment of colorectal cancer
Xgeva (denosumab) - For the prevention of skeletal-related events in patients with bone metastases from solid tumors
Xgeva (denosumab) - For the treatment of giant cell tumor of bone
Benefits
-5 weeks of vacation a year (including 2 annual, week-long company-wide paid shut downs)
-Beautiful, state-of-the-art global headquarters and facilities with a full list of amenities including a gym and daycare center onsite
-401K Plan: Amgen contributes 5% to employee’s 401k, even if employee elects not to participate in the plan. In addition, Amgen matches 100% of the first 5% of employee’s eligible contribution to 401(k). There is no vesting period. The cap of what employee can contribute is what the federal government allows which is $18,500 for 2019
- All Benefits kick in on day 1 (no grace period)